Marksans Pharma Ltd (NSE:MARKSANS)

Q2 2025 Marksans Pharma Ltd Earnings Call Transcript

Nov 13, 2024 / 11:30 AM GMT

Release Date Price: ₹305.7 (+1.73%)

Transcript

Key Points

Positve

Marksans Pharma Ltd (BOM:524404) reported a strong revenue growth of 20.8% year-on-year for Q2 FY25, driven by robust performance in the US, Australia, and New Zealand markets.
The US market saw a significant increase in revenue by 36.8% year-on-year, attributed to new product launches and increased market share.
Gross margin expanded by 732 basis points to 59.7% in Q2 FY25, due to a better product mix and reduced raw material prices.
The company achieved an all-time high quarterly EBITDA of INR 135.7 crores, marking a 19.1% increase year-on-year.
Marksans Pharma Ltd (BOM:524404) remains debt-free with a cash balance of INR 657 crores as of September 30, 2024, indicating strong financial health.

Negative

The UK and Europe markets experienced a relatively soft quarter due to seasonality, impacting overall growth in these regions.
Capacity utilization at the Teva facility is currently at 40%, indicating underutilization of resources.
Freight costs increased significantly, impacting overall expenses, with costs rising from $6,000 to $12,500, although they have recently improved.
The company faces challenges in finding suitable merger and acquisition targets, with high valuations being a deterrent.
Inventory levels have increased due to new product launches, which may affect cash flow until these products translate into sales.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MARK.NS - Marksans Pharma Ltd
Q2 2025 Marksans Pharma Ltd Earnings Call
Nov 13, 2024 / 11:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day. And welcome to Maxson Pharma Q2 F 25 conference call hosted by Ilara Securities India Private Limited.

As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call? Please signal an operator by pressing star then zero on your touchtone phone.

Please note that this conference is being recorded.

I now in the conference over to Mr Ksis Thakur from Pilar Security India Private Limited. Thank you and over to you, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.